Do you know that 1 in 2 heart attacks are repeat episodes? It’s time to get to the heart of the issue and improve the lives of the 60 million people living with cardio-vascular diseases in the EU. Read more in this blog by the EFPIA CVD Platform.

Despite representing 15% of health spending on average across Europe for the past 20 years, pharmaceutical expenditure has long been a focal point of health authorities and political debates. A broader understanding is needed about the role of investment in therapeutic innovation to deliver improved health outcomes, cost offsets for health systems, and to generate productive economies.

Watch the recording of the EFPIA event at Gastein 2023 to discuss whether medicines are affordable for health systems.

As currently written, the proposals would have a negative impact on the development of 45 products in Europe corresponding to a 12% decrease in innovation. This could deprive around 1.5 million European rare disease patients of a novel treatment option and would mean a further decrease by €4.5 billion in R&D spending in Europe. Read more in our new report.